Diagnostic efficiency and safety of rapid on‐site evaluation combined with CT‐guided transthoracic core needle biopsy in suspected lung cancer patients

作者：Ruzetuoheti Yiminniyaze, Xiujuan Zhang, Yuanyuan Zhang, Yuanyuan Zhang, Kun Chen, Chengwei Li, Ning Zhu, Daibing Zhou, Jing Li, Yuhai Zhang, Yuhai Zhang, Shengqing Li · 发表于：Cytopathology · 年份：2022 · DOI：10.1111/cyt.13123 · 被引用次数：17 · 研究领域：Lung Cancer Diagnosis and Treatment、Pleural and Pulmonary Diseases、Hepatocellular Carcinoma Treatment and Prognosis

OBJECTIVE: The efficacy of rapid on-site evaluation (ROSE) combined with computed tomography-guided transthoracic core needle biopsy (CT-guided TCNB) is rarely investigated. This study aimed to evaluate the diagnostic efficiency and safety of ROSE combined with CT-guided TCNB for suspected lung cancer patients. MATERIALS AND METHODS: Clinical data from 285 patients who received CT-guided TCNB for suspected lung cancer in Huashan Hospital from 2015 to 2018 were retrospectively analysed. Of these 163 patients underwent CT-guided TCNB combined with ROSE (ROSE group), while the remaining 122 patients underwent without ROSE (non-ROSE group). The smears from TCNB were quickly processed with Diff-Quick staining and analysed by a skilled cytologist on-site. The consistency of ROSE with the final clinicopathological diagnosis and the diagnostic efficiency and safety of ROSE combined with CT-guided TCNB in suspected lung cancer patients were evaluated. RESULTS: ROSE was highly concordant with pathological diagnosis (κ = 0.791; P < 0.001), with an accuracy of 95.7%. Diagnostic accuracy was significantly higher in the ROSE compared with the non-ROSE group (96.3% vs 86.1%; P = 0.002), with overall incidences of complications of 36.8% and 23.8%, respectively. Minor pneumothorax without drainage was slightly greater in the ROSE compared with the non-ROSE group (14.1% vs 6.6%; P = 0.046). However, there was no significant difference in serious complications between the two groups. CONCLUSION...